AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from its Phase 3 LUNA clinical trial.

The study assessed atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, as a preventive medication for adults experiencing menstrual migraines.

Primary Endpoint Achieved

Trial investigators administered atogepant for seven consecutive days, beginning three days before the start of menstruation, spanning three menstrual cycles.

The medication successfully met its primary endpoint, demonstrating a greater reduction in perimenstrual migraine days when compared to a placebo.

Participants taking atogepant recorded an average reduction of 1.20 migraine days, compared to a 0.40-day reduction for the placebo group. This translates to 0.80 fewer migraine days for patients using the active treatment.

Secondary Outcomes And Safety Profile

Atogepant achieved statistical significance across all eight ranked secondary endpoints.

The treatment delivered clinically meaningful improvements regarding overall headache burden, the need for acute medication, functional disability, and cognitive function.

Commercial Footprint

Atogepant directly targets a pathway responsible for migraines. The preventive drug already holds regulatory approval in 60 countries worldwide.

The company actively markets the medication as AQUIPTA within the European Union and as QULIPTA across the U.S., Canada, Israel, and Puerto Rico.

ABBV Price Action: AbbVie shares were up 0.39% at $251.89 at the time of publication on Thursday, according to Benzinga Pro data.

Photo: Shutterstock